Bruising Budget strengthens resolve
15 May, 2014The biotech sector is regrouping after the bruising Federal Budget on Tuesday night delivered a round of cuts for biotechnology, including measures to reduce the R&D Tax Incentive and abolish the Innovation Investment Fund (IIF) and Commercialisation Australia (CA).
Clinuvel raises $7.2m for Scenesse development
14 May, 2014 by Dylan Bushell-EmblingClinuvel Pharmaceuticals (ASX:CUV) has closed a $7.2m private placement, to help fund development of Scenesse in vitiligo and a post-marketing study of the drug in EPP.
Dimerix names new director, scientific advisor
13 May, 2014 by Dylan Bushell-EmblingDimerix has hired former Calzada chairman David Franklyn as a non-executive director, and veteran scientist Dr Brian Richardson as part of its scientific advisory team.
CSL opens recombinant therapy plant in Vic
13 May, 2014 by Dylan Bushell-EmblingCSL (ASX:CSL) has opened a biotechnology manufacturing plant in Melbourne as part of a $257m expansion of its Broadmeadows facilities.
Tension high as Federal Budget looms
13 May, 2014Reports of potential reduction of industry-support programs, on the back of the Commission of Audit report, are causing angst in the biotech sector as the industry fears decisions that could seriously damage Australia's hard-won momentum in innovation.
Admedus closes $8m placement
12 May, 2014 by Dylan Bushell-EmblingAdmedus (ASX:AHZ) has raised $8m in a placement, with plans to put the proceeds towards expanding its US and EU reach for CardioCel and to help fund a phase II trial of its HSV-2 vaccine.
3D-printed mouthpiece to treat sleep apnoea
12 May, 2014A new 3D-printed customised mouthpiece is set to provide relief for patients with sleep apnoea.
GI Dynamics expands reach of EndoBarrier in AU
12 May, 2014 by Dylan Bushell-EmblingGI Dynamics (ASX:GID) has revealed that two more Australian sites are offering its obesity and diabetes device therapy EndoBarrier and has published research into the treatment's mechanism of action.
dorsaVi's new CFO to lay foundation for growth
08 May, 2014 by Dylan Bushell-EmblingJerome Whelan has joined Melbourne-based motion analysis device developer dorsaVi as CFO to help the company set the stage for its international expansion.
Employee share schemes need repair in Budget
08 May, 2014As the Federal Budget looms, AusBiotech and Employee Ownership Australia and New Zealand are urging the government to remove impediments to Australian innovation by returning Employee Share Scheme (ESS) provisions to the pre-2009 position.
pSivida implant provides sustained antibody release
08 May, 2014 by Dylan Bushell-EmblingpSivida (ASX:PVA) has announced the findings of preclinical research showing that its Tethadur implant can provide long-term sustained release of Avastin and other antibody treatments.
Clinuvel recruiting for phase II vitiligo trial
06 May, 2014 by Dylan Bushell-EmblingClinuvel (ASX:CUV) has been cleared to commence recruiting for a phase II trial of Scenesse - a subdermal implant for treating melanin-based skin disorders - in vitiligo.
Express your interest in Medtech Industry Development Workshop
06 May, 2014The Australian Government is pleased to partner with industry to assist small businesses navigate Australian regulation and commercial growth pathways and invite expressions of interest in attending this free limited course in Melbourne on 26 May or Sydney on 2 June 2014.
Commission of Audit recommends cuts for industry, research and education
06 May, 2014 by Susan WilliamsonSome of the key recommendations in the recently released National Commission of Audit would remove support for the biotech and life sciences sector.
GI Dynamics raises $34.3m for EndoBarrier trial
05 May, 2014 by Dylan Bushell-EmblingGI Dynamics (ASX:GID) has raised $34.3m through a placement round to help fund its US phase II trial and other commercialisation efforts for EndoBarrier, its obesity and type 2 diabetes treatment.
